{"product_id":"textbook-of-pharmacoepidemiology-isbn-9781119701071","title":"Textbook of Pharmacoepidemiology","description":"\u003cp\u003ePharmacoepidemiology originally arose from the union of the fields of clinical pharmacology and epidemiology. Pharmacoepidemiology studies the use of and the effects of medical products in large numbers of people and applies the methods of epidemiology to the content area of clinical pharmacology. This field represents the science underlying studies of the effects of medical products (such as drugs, biologicals, and devices) in real world use.  \u003c\/p\u003e \u003cp\u003eStrom’s \u003ci\u003eTextbook of Pharmacoepidemiology\u003c\/i\u003e meets the increasing need for people to be trained in the field. Designed to meet the need of students, this textbook offers an approach that focuses on the core of the discipline, providing a focused educational resource for students. The book is designed for students at all levels: upper-level undergraduates, graduate students, post-doctoral fellows, and others who are learning the field. Case examples feature in most chapters, and all chapters include key points and a list of further reading. \u003c\/p\u003e \u003cp\u003eFully revised and updated throughout, \u003ci\u003eTextbook of Pharmacoepidemiology, 3rd edition\u003c\/i\u003e is a useful introduction and resource for students of pharmacoepidemiology, both those enrolled in formal classes and those learning in “the real world,” who will respond to the challenges that they encounter.  \u003c\/p\u003e \u003cp\u003eContributors xvii\u003c\/p\u003e \u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003eAcknowledgements xxv\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Introduction to Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 What is Pharmacoepidemiology? \u003c\/b\u003e\u003cb\u003e3\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 3\u003c\/p\u003e \u003cp\u003eDefinition of Pharmacoepidemiology 3\u003c\/p\u003e \u003cp\u003eHistorical Background 5\u003c\/p\u003e \u003cp\u003eThe Current Drug Approval Process 13\u003c\/p\u003e \u003cp\u003ePotential Contributions of Pharmacoepidemiology 15\u003c\/p\u003e \u003cp\u003eKey Points 18\u003c\/p\u003e \u003cp\u003eFurther Reading 18\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Study Designs Available for Pharmacoepidemiologic Studies \u003c\/b\u003e\u003cb\u003e20\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 20\u003c\/p\u003e \u003cp\u003eOverview of the Scientific Method 20\u003c\/p\u003e \u003cp\u003eTypes of Errors that one Can Make in Performing a Study 22\u003c\/p\u003e \u003cp\u003eCriteria for the Causal Nature of an Association 23\u003c\/p\u003e \u003cp\u003eEpidemiologic Study Designs 26\u003c\/p\u003e \u003cp\u003eDiscussion 31\u003c\/p\u003e \u003cp\u003eConclusion 32\u003c\/p\u003e \u003cp\u003eKey Points 32\u003c\/p\u003e \u003cp\u003eFurther Reading 33\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Sample Size Considerations for Pharmacoepidemiologic Studies \u003c\/b\u003e\u003cb\u003e35\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 35\u003c\/p\u003e \u003cp\u003eSample Size Calculations for Cohort Studies 35\u003c\/p\u003e \u003cp\u003eSample Size Calculations for Case–Control Studies 40\u003c\/p\u003e \u003cp\u003eSample Size Calculations for Case Series 41\u003c\/p\u003e \u003cp\u003eDiscussion 43\u003c\/p\u003e \u003cp\u003eKey Points 45\u003c\/p\u003e \u003cp\u003eFurther Reading 45\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies \u003c\/b\u003e\u003cb\u003e47\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJeffrey S. Barrett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 47\u003c\/p\u003e \u003cp\u003eClinical Pharmacology and Pharmacoepidemiology 48\u003c\/p\u003e \u003cp\u003eBasics of Clinical Pharmacology 48\u003c\/p\u003e \u003cp\u003ePharmacokinetics 49\u003c\/p\u003e \u003cp\u003eSpecial Populations 52\u003c\/p\u003e \u003cp\u003ePharmacodynamics 56\u003c\/p\u003e \u003cp\u003ePharmacogenomics 59\u003c\/p\u003e \u003cp\u003eModel-Informed\u003c\/p\u003e \u003cp\u003eDrug Development 59\u003c\/p\u003e \u003cp\u003eConclusion 60\u003c\/p\u003e \u003cp\u003eKey Points 60\u003c\/p\u003e \u003cp\u003eFurther Reading 61\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 When Should One Perform Pharmacoepidemiologic Studies? \u003c\/b\u003e\u003cb\u003e62\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 62\u003c\/p\u003e \u003cp\u003eReasons to Perform Pharmacoepidemiologic Studies 62\u003c\/p\u003e \u003cp\u003eSafety Versus Risk 67\u003c\/p\u003e \u003cp\u003eRisk Tolerance 67\u003c\/p\u003e \u003cp\u003eConclusion 70\u003c\/p\u003e \u003cp\u003eKey Points 70\u003c\/p\u003e \u003cp\u003eFurther Reading 71\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Views from Academia, Industry, Regulatory Agencies, and the Legal System \u003c\/b\u003e\u003cb\u003e73\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJoshua J. Gagne, Jerry Avorn, Nicolle M. Gatto, Jingping Mo, Gerald J. Dal Pan, June Raine, Shinobu Uzu, Aaron S. Kesselheim, and Kerstin N. Vokinger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe View from Academia 73\u003c\/p\u003e \u003cp\u003eThe View from Industry 81\u003c\/p\u003e \u003cp\u003eThe View from Regulatory Agencies 90\u003c\/p\u003e \u003cp\u003eThe View from the Legal System 98\u003c\/p\u003e \u003cp\u003eFurther Reading 107\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Sources of Pharmacoepidemiology Data \u003c\/b\u003e\u003cb\u003e113\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Postmarketing Spontaneous Pharmacovigilance Reporting Systems \u003c\/b\u003e\u003cb\u003e115\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGerald J. Dal Pan, Marie Lindquist, and Kate Gelperin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 115\u003c\/p\u003e \u003cp\u003eDescription 116\u003c\/p\u003e \u003cp\u003eStrengths 128\u003c\/p\u003e \u003cp\u003eLimitations 129\u003c\/p\u003e \u003cp\u003eParticular Applications 131\u003c\/p\u003e \u003cp\u003eThe Future 132\u003c\/p\u003e \u003cp\u003eKey Points 132\u003c\/p\u003e \u003cp\u003eFurther Reading 134\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Overview of Electronic Databases in Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e136\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 136\u003c\/p\u003e \u003cp\u003eDescription 137\u003c\/p\u003e \u003cp\u003eStrengths 138\u003c\/p\u003e \u003cp\u003eWeaknesses 139\u003c\/p\u003e \u003cp\u003eParticular Applications 140\u003c\/p\u003e \u003cp\u003eThe Future 140\u003c\/p\u003e \u003cp\u003eKey Points 141\u003c\/p\u003e \u003cp\u003eFurther Reading 141\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Encounter Databases \u003c\/b\u003e\u003cb\u003e142\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eTobias Gerhard, Yola Moride, Anton Pottegård, and Nicole Pratt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 142\u003c\/p\u003e \u003cp\u003eDescription 142\u003c\/p\u003e \u003cp\u003eStrengths 161\u003c\/p\u003e \u003cp\u003eLimitations 162\u003c\/p\u003e \u003cp\u003eParticular Applications 163\u003c\/p\u003e \u003cp\u003eThe Future 166\u003c\/p\u003e \u003cp\u003eKey Points 167\u003c\/p\u003e \u003cp\u003eFurther Reading 171\u003c\/p\u003e \u003cp\u003eUS Databases 172\u003c\/p\u003e \u003cp\u003eEuropean Databases 172\u003c\/p\u003e \u003cp\u003eCanadian Databases 173\u003c\/p\u003e \u003cp\u003eAsian Databases 173\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Electronic Health Record Databases \u003c\/b\u003e\u003cb\u003e174\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDaniel B. Horton, Harshvinder Bhullar, Francesca Cunningham, Janet Sultana, and Gialuca Trifirò\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 174\u003c\/p\u003e \u003cp\u003eDescription 174\u003c\/p\u003e \u003cp\u003eStrengths 184\u003c\/p\u003e \u003cp\u003eLimitations 185\u003c\/p\u003e \u003cp\u003eThe Future 186\u003c\/p\u003e \u003cp\u003eSummary Points for Electronic Health Record Databases 187\u003c\/p\u003e \u003cp\u003eAcknowledgment 187\u003c\/p\u003e \u003cp\u003eFurther Readings 189\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Primary Data Collection for Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e192\u003c\/b\u003e\u003cbr\u003e Priscilla Velentgas\u003c\/p\u003e \u003cp\u003eIntroduction 192\u003c\/p\u003e \u003cp\u003eMethods of Primary Data Collection 195\u003c\/p\u003e \u003cp\u003eStrengths 197\u003c\/p\u003e \u003cp\u003eLimitations 197\u003c\/p\u003e \u003cp\u003eParticular Applications 198\u003c\/p\u003e \u003cp\u003eConclusions 199\u003c\/p\u003e \u003cp\u003eKey Points 199\u003c\/p\u003e \u003cp\u003eFurther Reading 201\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 How Should One Perform Pharmacoepidemiologic Studies? Choosing Among the Available Alternatives \u003c\/b\u003e\u003cb\u003e203\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 203\u003c\/p\u003e \u003cp\u003eChoosing Among the Available Approaches to Pharmacoepidemiologic Studies 203\u003c\/p\u003e \u003cp\u003eExamples 215\u003c\/p\u003e \u003cp\u003eConclusion 216\u003c\/p\u003e \u003cp\u003eKey Points 216\u003c\/p\u003e \u003cp\u003eFurther Reading 216\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Special Issues in Pharmacoepidemiology Methodology \u003c\/b\u003e\u003cb\u003e219\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Validity of Drug and Diagnosis Data in Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e221\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMary Elizabeth Ritchey, Suzanne L. West, and George Maldonado\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 221\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 221\u003c\/p\u003e \u003cp\u003eMethodological Problems to be Solved by Pharmacoepidemiologic Research 222\u003c\/p\u003e \u003cp\u003eCurrently Available Solutions 233\u003c\/p\u003e \u003cp\u003eThe Future 242\u003c\/p\u003e \u003cp\u003eKey Points 242\u003c\/p\u003e \u003cp\u003eFurther Reading 243\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Assessing Causality from Case Reports \u003c\/b\u003e\u003cb\u003e246\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eBernard Bégaud and Judith K. Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 246\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 246\u003c\/p\u003e \u003cp\u003eThe Two Paradigms of Causality Assessment 246\u003c\/p\u003e \u003cp\u003eWhen is Assessing Causation from Cases Reports Useful? 247\u003c\/p\u003e \u003cp\u003eMethodological Problems to be Addressed by Pharmacoepidemiologic Research 248\u003c\/p\u003e \u003cp\u003eApproaches for Assessing Causation from Individual Cases 249\u003c\/p\u003e \u003cp\u003eCalibration 253\u003c\/p\u003e \u003cp\u003eChoosing the Appropriate Approach 253\u003c\/p\u003e \u003cp\u003eThe Future 254\u003c\/p\u003e \u003cp\u003eKey Points 255\u003c\/p\u003e \u003cp\u003eFurther Reading 255\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Molecular Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e257\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eChristine Y. Lu and Stephen E. Kimmel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 257\u003c\/p\u003e \u003cp\u003eDefinitions and Concepts 258\u003c\/p\u003e \u003cp\u003eThe Interface of Pharmacogenetics and Pharmacogenomics with Molecular\u003c\/p\u003e \u003cp\u003ePharmacoepidemiology 259\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 260\u003c\/p\u003e \u003cp\u003eThe Progression and Clinical Application of Molecular Pharmacoepidemiology 264\u003c\/p\u003e \u003cp\u003eMethodological Problems to be Addressed by Pharmacoepidemiologic Research 264\u003c\/p\u003e \u003cp\u003eCurrently Available Solutions 269\u003c\/p\u003e \u003cp\u003eThe Future 271\u003c\/p\u003e \u003cp\u003eKey Points 273\u003c\/p\u003e \u003cp\u003eFurther Reading 274\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Bioethical Issues in Pharmacoepidemiologic Research \u003c\/b\u003e\u003cb\u003e276\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eLaura E. Bothwell, Annika Richterich, and Jeremy Greene\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 276\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 276\u003c\/p\u003e \u003cp\u003eMethodologic Problems to be Solved by Pharmacoepidemiologic Research 283\u003c\/p\u003e \u003cp\u003eCurrently Available Solutions 286\u003c\/p\u003e \u003cp\u003eThe Future 289\u003c\/p\u003e \u003cp\u003eAcknowledgement 291\u003c\/p\u003e \u003cp\u003eKey Points 291\u003c\/p\u003e \u003cp\u003eFurther Reading 293\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 The Use of Randomized Controlled Trials for Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e294\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSamuel M. Lesko, Allen A. Mitchell, and Robert F. Reynolds\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 294\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 294\u003c\/p\u003e \u003cp\u003eMethodological Problems to be Solved by Pharmacoepidemiologic Research 296\u003c\/p\u003e \u003cp\u003eCurrently Available Solutions 298\u003c\/p\u003e \u003cp\u003eLarge Simple Trials 298\u003c\/p\u003e \u003cp\u003eAnalysis 303\u003c\/p\u003e \u003cp\u003ePrimary Analysis 303\u003c\/p\u003e \u003cp\u003eThe Future 304\u003c\/p\u003e \u003cp\u003eKey Points 305\u003c\/p\u003e \u003cp\u003eFurther Reading 305\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Pharmacoeconomics: Economic Evaluation of Pharmaceuticals \u003c\/b\u003e\u003cb\u003e307\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKevin A. Schulman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 307\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoeconomic Research 307\u003c\/p\u003e \u003cp\u003eMethodological Problems to be Addressed by Pharmacoeconomic Research 312\u003c\/p\u003e \u003cp\u003eThe Future 320\u003c\/p\u003e \u003cp\u003eAcknowledgements 320\u003c\/p\u003e \u003cp\u003eKey Points 320\u003c\/p\u003e \u003cp\u003eFurther Reading 320\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Patient Engagement and Patient Reported Outcomes \u003c\/b\u003e\u003cb\u003e322\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eEsi M. Morgan and Adam C. Carle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 322\u003c\/p\u003e \u003cp\u003ePatient Reported Outcomes in Clinical Trials 323\u003c\/p\u003e \u003cp\u003ePatient Reported Outcomes in Routine Care 323\u003c\/p\u003e \u003cp\u003ePatient Reported Outcomes as Motivation to Develop New Therapeutic Strategies 325\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 326\u003c\/p\u003e \u003cp\u003eMethodologic Problems to be Solved by Pharmacoepidemiologic Research 328\u003c\/p\u003e \u003cp\u003eCurrently Available Solutions 328\u003c\/p\u003e \u003cp\u003eThe Future 330\u003c\/p\u003e \u003cp\u003eKey Points 331\u003c\/p\u003e \u003cp\u003eFurther Reading 331\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 The Use of Meta-analysis in Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e334\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBrenda J. Crowe, Stephen J.W. Evans, H. Amy Xia, and Jesse A. Berlin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 334\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 335\u003c\/p\u003e \u003cp\u003eMethodological Problems to be Solved by Pharmacoepidemiologic Research 336\u003c\/p\u003e \u003cp\u003eCurrently Available Solutions 338\u003c\/p\u003e \u003cp\u003eThe Future 350\u003c\/p\u003e \u003cp\u003eKey Points 351\u003c\/p\u003e \u003cp\u003eFurther Reading 352\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Studies of Medication Adherence \u003c\/b\u003e\u003cb\u003e355\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJulie Lauffenburger, Trisha Acri, and Robert Gross\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 355\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 356\u003c\/p\u003e \u003cp\u003eMethodological Problems to be Addressed by Pharmacoepidemiologic Research 357\u003c\/p\u003e \u003cp\u003eCurrently Available Solutions 357\u003c\/p\u003e \u003cp\u003eAnalysis Issues in Adherence 362\u003c\/p\u003e \u003cp\u003eUse of Adherence Data in Clinical Trials and Comparative Effectiveness Studies 362\u003c\/p\u003e \u003cp\u003eThe Future 365\u003c\/p\u003e \u003cp\u003eKey Points 365\u003c\/p\u003e \u003cp\u003eFurther Reading 366\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies \u003c\/b\u003e\u003cb\u003e368\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSebastian Schneeweiss and Samy Suissa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 368\u003c\/p\u003e \u003cp\u003eClinical Problems to be Addressed by Pharmacoepidemiologic Research 368\u003c\/p\u003e \u003cp\u003eMethodological Problems to be Addressed by Pharmacoepidemiologic Research 368\u003c\/p\u003e \u003cp\u003eCurrently Available Solutions 370\u003c\/p\u003e \u003cp\u003eConclusion 382\u003c\/p\u003e \u003cp\u003eKey Points 382\u003c\/p\u003e \u003cp\u003eFurther Reading 384\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Special Applications and the Future of Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e387\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Special Applications of Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e389\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDavid Lee, Björn Wettermark, Christine Y. Lu, Stephen B. Soumerai, Robert T. Chen, Sharon-Lise T.\u003c\/i\u003e\u003ci\u003eNormand, Art Sedrakyan, Danica Marinac-Dabic, Daniel B. Horton, Sonia Hernandez-Diaz, Tamar \u003c\/i\u003e\u003ci\u003eLasky, Krista F. Huybrechts, Claudia Manzo, Emil Cochino, Hanna M. Seidling, David W. Bates, \u003c\/i\u003e\u003ci\u003eBennett Levitan, Rachael L. DiSantostefano, and Scott Evans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eStudies of Drug Utilization 389\u003c\/p\u003e \u003cp\u003eIntroduction 389\u003c\/p\u003e \u003cp\u003eEvaluating and Improving Prescribing 398\u003c\/p\u003e \u003cp\u003eSpecial Methodological Issues in Pharmacoepidemiologic Studies of Vaccine Safety 403\u003c\/p\u003e \u003cp\u003eEpidemiologic Studies of Implantable Medical Devices 408\u003c\/p\u003e \u003cp\u003eResearch on the Effects of Medications in Pregnancy and in Children 418\u003c\/p\u003e \u003cp\u003eRisk Management 427\u003c\/p\u003e \u003cp\u003eThe Pharmacoepidemiology of Medication Errors 436\u003c\/p\u003e \u003cp\u003eBenefit–Risk Assessments of Medical Treatments 442\u003c\/p\u003e \u003cp\u003eFurther Reading 454\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 The Future of Pharmacoepidemiology \u003c\/b\u003e\u003cb\u003e464\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eBrian L. Strom, Stephen E. Kimmel, and Sean Hennessy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 464\u003c\/p\u003e \u003cp\u003eThe View from Academia 465\u003c\/p\u003e \u003cp\u003eScientific Developments 465\u003c\/p\u003e \u003cp\u003eThe View from Industry 471\u003c\/p\u003e \u003cp\u003eThe View from Regulatory Agencies 472\u003c\/p\u003e \u003cp\u003eThe View from the Law 473\u003c\/p\u003e \u003cp\u003eConclusion 473\u003c\/p\u003e \u003cp\u003eKey Points 473\u003c\/p\u003e \u003cp\u003eFurther Reading 474\u003c\/p\u003e \u003cp\u003eAppendix A — Sample Size Tables 475\u003c\/p\u003e \u003cp\u003eAppendix B — Glossary 493\u003c\/p\u003e \u003cp\u003eIndex 505\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAbout the Editors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eBrian L. Strom\u003c\/b\u003e is Chancellor, Rutgers Biomedical and Health Sciences, University Professor, and Executive Vice President for Health Affairs, Rutgers University, Newark, NJ, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eStephen E. Kimmel\u003c\/b\u003e is Dean’s Professor and Chair of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, FL, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eSean Hennessy \u003c\/b\u003eis Professor of Epidemiology and Director of the Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.  \u003c\/p\u003e\u003cp\u003eTextbook of \u003cb\u003ePharmacoepidemiology, Third Edition\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePharmacoepidemiology originally arose from the union of the fields of clinical pharmacology and epidemiology. Pharmacoepidemiology studies the use of and the effects of medical products in large numbers of people and applies the methods of epidemiology to the content area of clinical pharmacology. This field represents the science underlying studies of the effects of medical products (such as drugs, biologicals, and devices) in real world use. \u003c\/p\u003e\u003cp\u003eStrom’s \u003ci\u003eTextbook of Pharmacoepidemiology\u003c\/i\u003e meets the increasing need for people to be trained in the field. Designed to meet the need of students, this textbook offers an approach that focuses on the core of the discipline, providing a focused educational resource for students. The book is designed for students at all levels: upper-level undergraduates, graduate students, post-doctoral fellows, and others who are learning the field. Case examples feature in most chapters, and all chapters include key points and a list of further reading. \u003c\/p\u003e\u003cp\u003eFully revised and updated throughout, \u003ci\u003eTextbook of Pharmacoepidemiology, Third edition\u003c\/i\u003e is a useful introduction and resource for students of pharmacoepidemiology, both those enrolled in formal classes and those learning in “the real world”, who will respond to the challenges that they encounter.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990146728165,"sku":"NP9781119701071","price":91.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119701071.jpg?v=1761786682","url":"https:\/\/k12savings.com\/es\/products\/textbook-of-pharmacoepidemiology-isbn-9781119701071","provider":"K12savings","version":"1.0","type":"link"}